Basilea News http://www.basilea.com/ Basilea News en Tue, 31 May 2016 03:52:11 +0200 Tue, 31 May 2016 03:52:11 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7032e387-fcb9-325b-58b2-57a72787c2e8 Thu, 21 Apr 2016 18:30:10 +0200 http://www.basilea.com/News-and-Media/Basilea-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-Ordinary-General-Meeting-of-Shareholders/7032e387-fcb9-325b-58b2-57a72787c2e8 <![CDATA[Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-AACR-meeting/101f964b-f449-654c-6ec0-c0ec3963b0e4
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
  • ]]>
    Thu, 21 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-data-on-clinical-oncology-programs-BAL101553-and-BAL3833-at-AACR-meeting/101f964b-f449-654c-6ec0-c0ec3963b0e4
    <![CDATA[Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program]]> http://www.basilea.com/News-and-Media/Basilea-awarded-contract-by-BARDA-of-up-to-USD-100-million-funding-for-ceftobiprole-phase-3-program/5d28fd52-0d0d-34f5-7f08-69db2d2d600e Wed, 20 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-awarded-contract-by-BARDA-of-up-to-USD-100-million-funding-for-ceftobiprole-phase-3-program/5d28fd52-0d0d-34f5-7f08-69db2d2d600e <![CDATA[Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)]]> http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-isavuconazole-and-ceftobiprole-data-at-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID/fe0cb1e4-64f9-af59-f229-f45d9b80f15c
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
  • ]]>
    Fri, 15 Apr 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-presentation-of-isavuconazole-and-ceftobiprole-data-at-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID/fe0cb1e4-64f9-af59-f229-f45d9b80f15c
    <![CDATA[Basilea issues agenda for Annual General Meeting of Shareholders]]> http://www.basilea.com/News-and-Media/Basilea-issues-agenda-for-Annual-General-Meeting-of-Shareholders/8084cc62-a399-5d4a-9e10-daa99c187b4f
  • Dr. Martin Nicklasson has determined not to stand for re-election as Chairman but will stand for re-election as Member of the Board
  • Domenico Scala nominated as new Chairman of the Board
  • ]]>
    Tue, 15 Mar 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-issues-agenda-for-Annual-General-Meeting-of-Shareholders/8084cc62-a399-5d4a-9e10-daa99c187b4f
    <![CDATA[Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis]]> http://www.basilea.com/News-and-Media/Basilea-announces-that-The-Lancet-Infectious-Diseases-published-results-from-the-CRESEMBA-isavuconazole-open-label-study-for-the-treatment-of-mucormycosis/8654679f-7fd0-7ff7-e0c3-f3985a13ec37 Wed, 09 Mar 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-announces-that-The-Lancet-Infectious-Diseases-published-results-from-the-CRESEMBA-isavuconazole-open-label-study-for-the-treatment-of-mucormycosis/8654679f-7fd0-7ff7-e0c3-f3985a13ec37 <![CDATA[Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany]]> http://www.basilea.com/News-and-Media/Basilea-launching-antifungal-CRESEMBA-isavuconazole-in-Germany/fab7a4fc-4d76-c91b-abee-9d8dd5dc7f4c Fri, 04 Mar 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-launching-antifungal-CRESEMBA-isavuconazole-in-Germany/fab7a4fc-4d76-c91b-abee-9d8dd5dc7f4c <![CDATA[Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom]]> http://www.basilea.com/News-and-Media/Basilea-launching-antifungal-CRESEMBA-isavuconazole-in-the-United-Kingdom/5496bdab-1424-378b-9b26-866c97a828ed Basel, Switzerland, March 03, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) hosts a symposium to support the launch of the new azole antifungal CRESEMBA® (isavuconazole) in the UK. The symposium will be held on March 3, 2016 as part of the 7th Advances Against Aspergillosis conference in Manchester, UK. It will be chaired by Prof. David W. Denning, Professor of Infectious Diseases, National Aspergillosis Centre, University of Manchester and will focus on current challenges and recent developments in the management of invasive mold infections.

    ]]>
    Thu, 03 Mar 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-launching-antifungal-CRESEMBA-isavuconazole-in-the-United-Kingdom/5496bdab-1424-378b-9b26-866c97a828ed
    <![CDATA[Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe]]> http://www.basilea.com/News-and-Media/Basilea-reports-solid-2015-full-year-results-and-is-launching-CRESEMBA-its-second-hospital-anti-infective-in-Europe/ba07f2d0-c675-ef99-6c09-0dea7ac3a49c
  • CRESEMBA® approval in U.S. and Europe and launched in the U.S. by Astellas
  • Zevtera® launched in major European countries
  • Tumor checkpoint controller BAL101553 interim phase 2a (i.v.) study data reported and phase 1 (oral) study initiated; oncology panRAF-SRC kinase inhibitor BAL3833 phase 1 initiated
  • CHF 200 million convertible bonds issued, year-end cash and short-term investments of CHF 364.7 million
  • ]]>
    Mon, 29 Feb 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-solid-2015-full-year-results-and-is-launching-CRESEMBA-its-second-hospital-anti-infective-in-Europe/ba07f2d0-c675-ef99-6c09-0dea7ac3a49c
    <![CDATA[GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program]]> http://www.basilea.com/News-and-Media/GSK-informs-Basilea-that-it-has-elected-not-to-continue-its-U-S-alitretinoin-program/b83c1ac3-cb42-0ed3-166d-4383646bf464 Thu, 21 Jan 2016 21:15:45 +0100 http://www.basilea.com/News-and-Media/GSK-informs-Basilea-that-it-has-elected-not-to-continue-its-U-S-alitretinoin-program/b83c1ac3-cb42-0ed3-166d-4383646bf464